Interferon alfa-2A
Highest phase reached
Approved
Drug type
Protein
First approval year
1986
- First approval year
- 1986
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Protein
- Drug name
- Interferon alfa-2A
- alpheon
- Alpheon
- canferon
- Canferon
- canferon a
- Canferon a
- cha ifnalpha2a
- Cha-ifnalpha2a
- roferon a
- Roferon a
- Roferon-a
- interferon alfa 2a
- Interferon Alfa 2a
- Interferon Alfa 2A
- interferon alfa 2a genetical recombination
- interferon alfa 2a jan
- interferon alfa 2a mi
- interferon alfa 2a recombinant
- interferon alfa 2a recombinant vandf
- interferon alfa 2a usan
- interferon alfa 2a vandf
- interferon alfa 2a who dd
- interferon alfa-2a
- Interferon alfa-2a
- Interferon Alfa-2a
- Interferon Alfa-2A
- INTERFERON ALFA-2A
- Interferon alfa-2a (genetical recombination)
- INTERFERON ALFA-2A (RECOMBINANT)
- INTERFERON ALFA-2A [JAN]
- INTERFERON ALFA-2A [MI]
- INTERFERON ALFA-2A [USAN]
- INTERFERON ALFA-2A [VANDF]
- Interferon alfa-2a [WHO-DD]
- INTERFERON ALFA-2A, RECOMBINANT
- INTERFERON ALFA-2A,RECOMBINANT
And 23 more, listed on the interactive page.
- ATC classification codes
- L03AB04
Sources for recorded values
- CAS registry numbers
- 76543-88-9
- ChEMBL ID
- CHEMBL2108508
- RxNorm IDs (RxCUI)
- 5879
- FDA ingredient codes (UNII)
- 47RRR83SK7
- Status
- refused
- Status date
- 5 Sept 2006
- Approved indications
- Adult patients with histologically proven chronic hepatitis C who are positive for hepatitis C virus (HCV) antibodies or HCV RNA and have elevated serum alanine aminotransferase (ALT) without liver decompensation.The efficacy of Interferon alfa-2a in the treatment of hepatitis C is enhanced when combined with ribavirin. Alpheon should be given alone mainly in case of intolerance or contra-indication to ribavirin.
- Product number
- EMEA/H/C/000585
- Authorisation holder
- BioPartners GmbH
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- Yes
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Hepatitis C, Chronic
European medicines record
- Patents
- 0
- Designations
- 3
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
Administration routes
- Parenteral
- Mechanism
- Interferon alpha/beta receptor agonist
- Action type
- Agonist
- Target
- Interferon alpha/beta receptor
- Protein identifier
- P17181
- Mechanism
- Interferon alpha/beta receptor agonist
- Action type
- Agonist
- Target
- Interferon alpha/beta receptor
- Protein identifier
- P48551
Open Targets mechanisms
- Mechanism
- Interferon alpha/beta receptor agonist
- Action type
- Agonist
- Target
- Interferon alpha/beta receptor
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Psoriasis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000681
- Subject identifier
- D002292
- Condition
- Melanoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- HIV Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Multiple Myeloma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Melanoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002617
- Subject identifier
- D008545
- Condition
- Hepatitis C
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003047
- Subject identifier
- D006526
- Condition
- Behcet Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003780
- Subject identifier
- D001528
- Condition
- Hepatitis C, Chronic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004220
- Subject identifier
- D019698
- Condition
- Leukemia, Hairy Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000956
- Subject identifier
- D007943
- Condition
- Retinal Vasculitis
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001156
- Subject identifier
- D031300
- Condition
- Kidney Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002367
- Subject identifier
- D007680
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition identifier
- EFO_0000220
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000676
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000681
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000756
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002617
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004220
- Highest recorded phase
- 2
- Condition identifier
- EFO_0008496
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000956
- Highest recorded phase
- 2
- Condition identifier
- HP_0001394
- Highest recorded phase
- 2
- Condition identifier
- HP_0003510
- Highest recorded phase
- 2
- Condition identifier
- HP_0031273
- Highest recorded phase
- 0
- Condition identifier
- MONDO_0000873
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002280
- Highest recorded phase
- 0
- Condition identifier
- MONDO_0002367
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002691
- Condition identifier
- MONDO_0004952
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004967
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005005
- Highest recorded phase
- 2
And 35 more, listed on the interactive page.
Warnings
- Warning
- Black Box Warning
Open Targets warnings
- Warning
- Black Box Warning
- Country
- United States
- Event
- anaemia
- Reports
- 2,176
- Reporting signal score
- 3,075.55
- Event
- anal pruritus
- Reports
- 5
- Reporting signal score
- 16.4712
- Event
- asthenia
- Reports
- 702
- Reporting signal score
- 199.591
- Event
- depression
- Reports
- 649
- Reporting signal score
- 404.727
- Event
- dysgeusia
- Reports
- 349
- Reporting signal score
- 377.337
- Event
- exposure via direct contact
- Reports
- 81
- Reporting signal score
- 344.539
- Event
- fatigue
- Reports
- 1,434
- Reporting signal score
- 470.06
- Event
- focal segmental glomerulosclerosis
- Reports
- 5
- Reporting signal score
- 13.4835
- Event
- haemoglobin decreased
- Reports
- 739
- Reporting signal score
- 714.906
- Event
- hepatic cirrhosis
- Reports
- 166
- Reporting signal score
- 236.412
- Event
- hepatic neoplasm malignant
- Reports
- 14
- Reporting signal score
- 57.8292
- Event
- hepatitis c
- Reports
- 367
- Reporting signal score
- 756.728
- Event
- hepatotoxicity
- Reports
- 11
- Reporting signal score
- 13.4289
- Event
- influenza like illness
- Reports
- 410
- Reporting signal score
- 393.072
- Event
- leukopenia
- Reports
- 449
- Reporting signal score
- 463.438
- Event
- liver iron concentration increased
- Reports
- 3
- Reporting signal score
- 16.2838
- Event
- metabolic disorder
- Reports
- 7
- Reporting signal score
- 17.2129
- Event
- nervous system disorder
- Reports
- 10
- Reporting signal score
- 13.6815
- Event
- neurological decompensation
- Reports
- 5
- Reporting signal score
- 13.9584
- Event
- neutropenia
- Reports
- 683
- Reporting signal score
- 438.618
- Event
- neutrophil count decreased
- Reports
- 335
- Reporting signal score
- 365.651
- Event
- pancytopenia
- Reports
- 419
- Reporting signal score
- 422.748
- Event
- platelet count decreased
- Reports
- 907
- Reporting signal score
- 1,086.1
- Event
- pruritus
- Reports
- 714
- Reporting signal score
- 316.475
- Event
- pyrexia
- Reports
- 792
- Reporting signal score
- 211.565
And 5 more, listed on the interactive page.
- NCT00000696
- NCT00000754
- NCT00000967
- NCT00001567
- NCT00083889
- NCT00502034
- NCT00520403
- NCT00719264
- NCT00738530
- NCT00796757
- NCT01513187
- NCT00167583
- NCT00204529
- NCT00308607
- NCT00323505
- NCT00381953
- NCT00416429
- NCT00433069
- NCT02340962
- NCT00483132
- NCT01404936
- NCT01609010
- NCT02159482
- NCT02763969
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (657)
- 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer
- 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
- A Clinical Study of JS005 in Patients With Ankylosing Spondylitis
- A Clinical Study of MIL93 in Solid Tumors.
- A Clinical Study of MIL95 in Advanced Malignancies.
- A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
- A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer
- A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults
- A Clinical Trial Aimed at Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer
- A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination
- A Clinical Trial to Evaluate a Recombinant Hepatitis E Vaccine in Healthy Adults
- A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)
- A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area
- A Pharmaco-epidemiological Study of Short Patients Born Small for Gestational Age (SGA), Treated With Saizen® (Recombinant Somatropin)
Approved for (2)
- Cancer
- Neoplasm
In development for (14)
- Acute lymphoblastic leukemia Phase 3
- Behcet disease Phase 3
- Chronic hepatitis C virus infection Phase 2
- Hairy cell leukemia Phase 2
- Hepatitis C virus infection Phase 3
- HIV infectious disease Phase 2
- Kidney cancer Phase 3
- Lymphoma Phase 3
- Melanoma Phase 3
- Metastatic melanoma Phase 3
- Plasma cell myeloma Phase 2
- Psoriasis Phase 1
- Renal cell carcinoma Phase 3
- Retinal vasculitis Phase 3